JP2015508892A - 慢性ｂ型肝炎患者の応答予測及び治療観察のためのｂ型肝炎ウイルス免疫複合体 - Google Patents

慢性ｂ型肝炎患者の応答予測及び治療観察のためのｂ型肝炎ウイルス免疫複合体 Download PDF

Info

Publication number
JP2015508892A
JP2015508892A JP2014557064A JP2014557064A JP2015508892A JP 2015508892 A JP2015508892 A JP 2015508892A JP 2014557064 A JP2014557064 A JP 2014557064A JP 2014557064 A JP2014557064 A JP 2014557064A JP 2015508892 A JP2015508892 A JP 2015508892A
Authority
JP
Japan
Prior art keywords
hbv
amount
immune complex
subject
interferon therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014557064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508892A5 (enExample
Inventor
クラウゼ，ウルスラ
ヒップ，ベルトホルト
グルナート，ファイト・ペーター
ウプマイヤー，バーバラ
ロパティン，ユーリ
ニート，アンニッキ デ
ニート，アンニッキ デ
リーシンク，ヘンク
ザーアイアー，ハンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2015508892A publication Critical patent/JP2015508892A/ja
Publication of JP2015508892A5 publication Critical patent/JP2015508892A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014557064A 2012-02-20 2013-02-18 慢性ｂ型肝炎患者の応答予測及び治療観察のためのｂ型肝炎ウイルス免疫複合体 Pending JP2015508892A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12156192.2A EP2629096A1 (en) 2012-02-20 2012-02-20 HBV immunocomplexes for response prediction and therapy monitoring of chronic HBV patients
EP12156192.2 2012-02-20
PCT/EP2013/053150 WO2013124229A1 (en) 2012-02-20 2013-02-18 Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients

Publications (2)

Publication Number Publication Date
JP2015508892A true JP2015508892A (ja) 2015-03-23
JP2015508892A5 JP2015508892A5 (enExample) 2016-04-07

Family

ID=47757571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557064A Pending JP2015508892A (ja) 2012-02-20 2013-02-18 慢性ｂ型肝炎患者の応答予測及び治療観察のためのｂ型肝炎ウイルス免疫複合体

Country Status (7)

Country Link
US (1) US20150192583A1 (enExample)
EP (2) EP2629096A1 (enExample)
JP (1) JP2015508892A (enExample)
CN (1) CN104126124A (enExample)
CA (1) CA2863106A1 (enExample)
HK (1) HK1203616A1 (enExample)
WO (1) WO2013124229A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016159178A1 (ja) * 2015-03-30 2016-10-06 雅史 溝上 インターフェロン治療効果予測方法及びそれを用いたｂ型肝炎患者の治療用医薬組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009303A1 (en) * 2015-07-15 2017-01-19 F. Hoffmann-La Roche Ag Biomarkers for hbv treatment response
WO2018087715A1 (en) * 2016-11-11 2018-05-17 Melbourne Health An assay for determining hepatitis b clearance
TW201928064A (zh) * 2017-12-21 2019-07-16 紐西蘭商紐西蘭健康創新中心管理有限公司 B型肝炎病毒之突變分析方法及其應用
US12235273B2 (en) 2018-05-04 2025-02-25 Abbott Laboratories HBV diagnostic, prognostic, and therapeutic methods and products
CN110564894B (zh) * 2019-09-10 2023-04-07 深圳市罗湖区人民医院 干扰物对荧光定量pcr检测hbv dna的干扰评价方法
CN111474187A (zh) * 2020-04-09 2020-07-31 三峡大学 一种免疫电镜免疫反应盒
CN115466802B (zh) * 2022-10-28 2023-12-12 北京大学 Tp53bp2在调控干扰素信号通路及抗病毒中的用途
WO2026105165A1 (en) * 2024-11-14 2026-05-21 Arkan Russul New kit for diagnosing hashimoto's disease (the fifth principle of elisa)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09511577A (ja) * 1994-03-31 1997-11-18 ザ スクリップス リサーチ インスティチュート 慢性肝炎ｂ型ウイルス感染の診断方法
JP2010526307A (ja) * 2007-05-08 2010-07-29 エフ．ホフマン−ラ ロシュ アーゲー 特異的免疫グロブリンクラスｇ抗体の検出方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5885700A (en) * 1999-06-22 2001-01-09 Chiron Corporation Method for treating chronic hbv infection
CN1261455C (zh) * 2002-07-19 2006-06-28 余宙耀 一种重组人源性抗乙肝表面抗原（HBsAg）Fab抗体及其制取方法
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
GB0326416D0 (en) * 2003-11-12 2003-12-17 Karolinska Innovations Ab Methods and means relating to hepatitis B infection
US20090170926A1 (en) * 2004-03-31 2009-07-02 Monash Univeristy Antiviral agents
AU2010236606A1 (en) * 2009-04-14 2011-11-03 Merck Sharp & Dohme Corp. Interferon-alfa sensitivity biomarkers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09511577A (ja) * 1994-03-31 1997-11-18 ザ スクリップス リサーチ インスティチュート 慢性肝炎ｂ型ウイルス感染の診断方法
JP2010526307A (ja) * 2007-05-08 2010-07-29 エフ．ホフマン−ラ ロシュ アーゲー 特異的免疫グロブリンクラスｇ抗体の検出方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016159178A1 (ja) * 2015-03-30 2016-10-06 雅史 溝上 インターフェロン治療効果予測方法及びそれを用いたｂ型肝炎患者の治療用医薬組成物

Also Published As

Publication number Publication date
US20150192583A1 (en) 2015-07-09
EP2817631A1 (en) 2014-12-31
EP2629096A1 (en) 2013-08-21
CA2863106A1 (en) 2013-08-29
CN104126124A (zh) 2014-10-29
HK1203616A1 (en) 2015-10-30
WO2013124229A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
US20150192583A1 (en) Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients
HUE027662T2 (en) Procedures for Determining Antibodies to Medicine
TW202311744A (zh) SARS-CoV-2之免疫測定方法及免疫測定套組
WO2024001044A1 (zh) 一种与肺癌相关的生物标志物组合、含其的试剂盒及其用途
US20220120737A1 (en) Method for detecting sars-cov-2-specific serum human immunoglobulins
WO2020141608A1 (ja) 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法
US20240103002A1 (en) Orthopoxvirus serology assays
JPWO2020075691A1 (ja) ロイシンリッチα２グリコプロテインの免疫測定方法及び測定試薬
JP6048923B2 (ja) Ｂ型慢性肝炎の検出方法および検出キット
US20190066846A1 (en) Method, apparatus, computer program product and kit for assisting recurrence risk prediction for hepatocellular carcinoma patients
US20220120759A1 (en) Methods for detection and characterization of anti-viral vector antibodies
Ou et al. Ultrasensitive monitoring of SARS-CoV-2-specific antibody responses based on a digital approach reveals one week of IgG seroconversion
CN111458522A (zh) 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用
JP7315965B2 (ja) ウィルス性肝癌の検出方法
JP7854592B2 (ja) 菌体外膜画分を用いた、ヘリコバクター・スイス抗体の検出法
KR102621473B1 (ko) 성인형 스틸병 진단용 바이오마커 조성물
JP7852839B2 (ja) 菌体可溶化画分を用いた、ヘリコバクター・スイス抗体の検出法
JP4636225B2 (ja) 検査試薬キット
JP7854593B2 (ja) 全菌体を用いた、ヘリコバクター・スイス抗体の検出法
CN120757639A (zh) 一种p-Tau217单分子检测试剂盒及其检测抗体
EP4720682A1 (en) Specific detection of homodimeric hnl
CN119241713A (zh) 定量检测基质金属蛋白酶7(mmp-7)的荧光层析试纸条、试剂盒及应用
US20070054264A1 (en) Methods and means relating to hepatitis b infection
Quarleri et al. HBV-coinfected patients: factors associated with response. JViral Hepat. 2007; 14: 176–82.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170628